单独或组合使用PARP抑制剂治疗前列腺癌
María Dolores Fenor de la Maza1, Jose Luis Pérez Gracia1, Bernardino Miñana2
1Department of Medical Oncology, Clínica Universidad de Navarra, Pamplona, Spain.
Therapeutic advances in urology
|August 26, 2024
概括
患有DNA修复异常的晚期前列腺癌患者可能受益于PARP抑制剂 (PARPi). 需要进一步的研究来改善患者选择和组合疗法的生物标志物.
科学领域:
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 在DNA修复途径中的基因组异常,特别是同源重组 (HR),在高达25%的晚期前列腺癌患者中发生.
- 这些异常,特别是BRCA突变,预测对多 (ADP-ribose) 聚合酶抑制剂 (PARPi) 的反应可能性更高.
研究的目的:
- 审查PARPi在晚期前列腺癌中的发展和疗效.
- 讨论PARPi作为单一药物和组合疗法的作用.
- 突出需要改进生物标志物和了解PARPi治疗耐药性机制的需要.
主要方法:
- 在前列腺癌中对PARPi进行临床试验和研究的文献综述.
- 分析与前列腺癌中DNA修复途径相关的基因组数据.
- 综合有关耐药机制和新生物标志物开发的信息.
主要成果:
- 临床试验证明了PARPi单独或组合在精选的前列腺癌患者中的有效性.
- 预测PARPi反应的生物标志物验证需要进一步改进,以优化患者选择.
- 了解耐药机制对于最大限度地提高临床效益和开发新的治疗策略至关重要.
结论:
- PARPi代表了高级前列腺癌的重要治疗选择,具有特定的DNA修复基因组异常.
- 对预测生物标志物和抗药机制的持续研究对于完善PARPi的使用和改善患者的治疗结果至关重要.
- 未来的方向包括优化PARPi组合,并将其整合到前列腺癌管理中.
相关概念视频
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
162
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
162
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
138
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
138
02:34Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
01:30Cancer Vaccines
347
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
347